Noninvasive assessment of liver fibrosis. Serum markers and transient elastography (FibroScan)

Revista Espanola de Enfermedades Digestivas

Volumn 101, Issue 11, 2009, Pages 787-799

  Marin Gabriel J C ^a   Solis Herruzo J A ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Fibroscan; Liver biopsy; Liver fibrosis; Serum markers; Transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ARTICLE; BLOOD ANALYSIS; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; DIAGNOSTIC TEST; DISEASE COURSE; ELASTOGRAPHY; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; NON INVASIVE PROCEDURE; PORTAL HYPERTENSION; PROGNOSIS; REPRODUCIBILITY; BLOOD; LIVER CIRRHOSIS;

BIOLOGICAL MARKERS; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER CIRRHOSIS;

EID: 77950342613     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082009001100006     Document Type: Article

References (100)

1. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006; 43(2 Supl. 1): S113-S120.
2. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49(3): 1017-44.
3. Solis-Herruzo JA, Munoz Yague MT. Assessment of hepatic fibrosis. Rev Esp Enferm Dig 1992; 81(2): 121-8.
4. Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver-biopsy -Results of a nationwide survey in Switzerland. Digestive Diseases and Sciences 1993; 38(8): 1480-4.
5. Thampanitchawong P, Piratvisuth T. Liver biopsy: complications and risk factors. World J Gastroenterol 1999; 5(4): 301-4.
6. Terjung B, Lemnitzer I, Dumoulin FL, Effenberger W, Brackmann HH, Sauerbruch T, et al. Bleeding complications after percutaneous liver biopsy. Digestion 2003; 67(3): 138-45.
7. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39(2): 239-44.
8. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97(10): 2614-8.
9. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38(6): 1449-57.
10. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003; 38: 427-32.
11. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20(1 Pt 1): 15-20.
12. Lang L. NIH Consensus Development Conference updates HCV management. Gastroenterology 2002; 123(2): 404.
13. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130(1): 231-64.
14. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38(2): 518-26.
15. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41(6): 1376-82.
16. Romera M, Corpas R, Romero Gomez M. Insulin resistance as a noninvasive method for the assessment of fibrosis in patients with hepatitis C: a comparative study of biochemical methods. Rev Esp Enferm Dig 2006; 98(3): 161-9.
17. Snyder N, Nguyen A, Gajula L, Soloway R, Xiao SY, Lau DT, et al. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin Chim Acta 2007; 381(2): 119-23.
18. Pissaia AJ, Borderie D, Bernard D, Scatton O, Calmus Y, Conti F. APRI and FIB-4 scores are useful after liver transplantation independently of etiology. Transplant Proc 2009; 41(2): 679-81.
19. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36(4): 986-92.
20. Gomez MR, del Campo MRM, Otero MA, Vallejo M, Corpas R, Castellano-Megias VM. Comparative study of two models that use biochemical parameters for the noninvasive diagnosis of fibrosis in patients with hepatitis C. Med Clin 2005; 124(20): 761-4.
21. Tural C, Tor J, Sanvisens A, Perez-Alvarez N, Martinez E, Ojanguren I, et al. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Clin Gastroenterol Hepatol 2009; 7(3): 339-45.
22. Loko MA, Castera L, Dabis F, Le Bail B, Winnock M, Coureau G, et al. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol 2008; 103(8): 1973-80.
23. Sebastiani G, Vario A, Guido M, Alberti A. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 2008; 15(3): 212-8.
24. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34(3): 428-34.
25. Thabut D, Simon M, Myers RP, Messous D, Thibault V, Imbert-Bismut F, et al. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 2003; 37(5): 1220-1.
26. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357(9262): 1069-75.
27. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepatitis 2002; 9(2): 128-33.
28. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003; 38(2): 481-92.
29. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T, grp M. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97(9): 2419-25.
30. Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, et al. The predictive value of fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology 2004; 39(3): 862-3.
31. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8.
32. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128(2): 343-50.
33. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clinical Chemistry 2003; 49(3): 450-4.
34. Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, et al. Longitudinal assessment of histology surrogate markers (Fibro-Test-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100(9): 1970-80.
35. Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. J Viral Hepat 2009; 16(3): 203-13.
36. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. Aids 2003; 17(5): 721-5.
37. Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42(4): 838-45.
38. Alric L, Kamar N, Bonnet D, Danjoux M, Abravanel F, Lauwers-Cances V, et al. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis. Transpl Int 2009.
39. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40.
40. Thabut D, Imbert-Bismut F, Cazals-Hatem D, Messous D, Muntenau M, Valla DC, et al. Relationship between the Fibrotest and portal hypertension in patients with liver disease. Aliment Pharmacol Ther 2007; 26(3): 359-68.
41. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clinical Chemistry 2004; 50(8): 1344-55.
42. Fontanges T, Bailly F, Trepo E, Chevallier M, Maynard-Muet M, Nalet B, et al. Discordance between biochemical markers of liver activity and fibrosis (ActitestR) (FibrotestR) and liver biopsy in patients with chronic hepatitis C. Gastroenterol Clin Biol 2008.
43. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43(6): 1317-25.
44. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and Fibro-Test. Hepatology 2007; 46(1): 32-6.
45. Mallet V, Dhalluin-Venier V, Roussin C, Bourliere M, Pettinelli ME, Giry C, et al. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2009; 29(4): 409-15.
46. Lok ASF, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort. Hepatology 2005; 42(2): 282-92.
47. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004; 39(5): 1239-47.
48. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konat A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42(6): 1373-81.
49. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51(10): 1867-73.
50. Bourliere M, Penaranda G, Ouzan D, Renou C, Botta-Fridlund D, Tran A, et al. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther 2008; 28(4): 458-67.
51. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45(2): 297-306.
52. Castiella A, Zapata E, Otazua P, Fernandez J, Alustiza JM, Ugarte M, et al. Utility of various non-invasive methods for fibrosis prediction among Basque Country patients with phenotypic hemochromatosis. Rev Esp Enferm Dig 2008; 100(10): 611-4.
53. McHutchison JG, Blatt LM, De Medina M, Craig JR, Conrad A, Schiff ER, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. J Gastroenterol Hepatol 2000; 15(8): 945-51.
54. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clinical Chemistry 1996; 42(4): 558-63.
55. Castera L, Hartmann DJ, Chapel F, Guettier C, Mal F, Lons T, et al. Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. J Hepatol 2000; 32(3): 412-8.
56. Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U, et al. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003; 39(2): 179-86.
57. Kossakowska AE, Edwards DR, Lee SS, Urbanski LS, Stabbler AL, Zhang CL, et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol 1998; 153(6): 1895-902.
58. Murawaki Y, Yamada S, Ikuta Y, Kawasaki H. Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. J Hepatol 1999; 30(6): 1090-8.
59. Walsh KM, Timms P, Campbell S, MacSween RNM, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C -Comparison using ROC analysis. Dig Dis Sci 1999; 44(3): 624-30.
60. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004; 99(2): 271-9.
61. Rosenberg WMC, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004; 127(6): 1704-13.
62. Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41(6): 935-42.
63. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. J Hepatol 2005; 43(1): 78-84.
64. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29(12): 1705-13.
65. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48(5): 835-47.
66. Bravo AA, Sheth SG, Chopra S. Current concepts: Liver biopsy. N Engl J Med 2001; 344(7): 495-500.
67. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56(7): 968-73.
68. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41(1): 48-54.
69. Moreno-Otero R, Trapero-Marugan M, Mendoza J. Liver fibrosis assessment by transient elastography in hepatitis C patients with normal alanine aminotransferase. Gut 2006; 55(7): 1055-6.
70. De Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41(2): 175-9.
71. Shaheen AAM, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: A systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102: 2589-600.
72. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Ledinghen V, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009; 29(2): 242-7.
73. Corpechot C, El Naggar A, Poujol-Robert A, Ziol M, Wendum D, Chazouilleres O, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43(5): 1118-24.
74. Gomez-Dominguez E, Mendoza J, Garcia-Buey L, Trapero M, Gisbert JP, Jones EA, et al. Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Aliment Pharmacol Ther 2008; 27(5): 441-7.
75. Gomez-Dominguez E, Mendoza J, Rubio S, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R. Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Aliment Pharmacol Ther 2006; 24(3): 513-8.
76. Yoneda M, Fujita K, Inamori M, Nakajima A, Tamano M, Hiraishi H. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). [Letter]. Gut 2007; 56(9): 1330-1.
77. Marin-Gabriel JC, De la Cruz J, Fernandez I, Martin AM, Munoz R, Colina F, et al. Prospective comparison between transient elastography (fibroscan), APRI and Forns' test for assessing liver fibrosis in patients with histological features of NAFLD. J Hepatol 2007; 46: S275.
78. Ganne-Carrie N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006; 44(6): 1511-7.
79. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55(3): 403-8.
80. Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45(5): 1290-7.
81. Kazemi F, Kettaneh A, N'Kontchou G, Pinto E, Ganne-Carriel N, Trinchet JC, et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol 2006; 45(2): 230-5.
82. Lim JK, Groszmann RJ. Transient elastography for diagnosis of portal hypertension in liver cirrhosis: is there still a role for hepatic venous pressure gradient measurement? Hepatology 2007; 45(5): 1087-90.
83. Bosch J. Predictions from a hard liver. J Hepatol 2006; 45(2): 174-7.
84. Carrion JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transplant 2006; 12(12): 1791-8.
85. Harada N, Soejima Y, Taketomi A, Yoshizumi T, Ikegami T, Yamashita YI, et al. Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation. Transplantation 2008; 85: 69-74.
86. Rigamonti C, Donato MF, Fraquelli M, Agnelli F, Ronchi G, Casazza G, et al. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation. Gut 2008; 57(6): 821-7.
87. de Ledinghen V, Le Bail B, Rebouissoux L, Fournier C, Foucher J, Miette V, et al. Liver stiffness measurement in children using FibroScan: Feasibility study and comparison with fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. Journal of Pediatric Gastroenterology and Nutrition 2007; 45: 443-50.
88. Mirault T, Lucidarme D, Turlin B, Vandevenne P, Gosset P, Ernst O, et al. Non-invasive assessment of liver fibrosis by transient elastography in post transfusional iron overload. Eur J Haematol 2008; 80(4): 337-40.
89. Adhoute X, Foucher J, Laharie D, Terrebonne E, Vergniol J, Castera L, et al. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. Gastroenterol Clin Biol 2008; 32(2):180-7.
90. Laharie D, Zerbib F, Adhoute X, Boue-Lahorgue X, Foucher J, Castera L, et al. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther 2006; 23(11): 1621-8.
91. Berends MAM, Snoek J, de Jong E, Van Krieken JH, de Knegt RJ, van Oijen MGH, et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and FibroscanR predicts the absence of significant liver fibrosis. Liver Int 2007; 27(5): 639-45.
92. Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepatitis 2007; 14(5): 360-9.
93. Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008; 47(2): 592-5.
94. Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47(2): 380-4.
95. Millonig G, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, B++chler MW, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008; 48(5): 1718-23.
96. Marin-Gabriel JC, De-la-Cruz JB, Rodriguez-Gil Y, Tocado M, Martin-Algibez A, Fernandez-Vazquez I, et al. Transient elastography (Fibroscan) significantly correlates with intrahepatic cholestasis in not related HCV liver diseases. A multivariate analysis. Gut 2008; 57(Supl. II): A52.
97. Lebray P, Varnous S, Charlotte F, Varaut A, Poynard T, Ratziu V. Liver Stiffness Is an Unreliable Marker of Liver Fibrosis in Patients with Cardiac Insufficiency. Hepatology 2008; 48(6): 2089.
98. Friedrich-Rust M, Ong MF, MartenS S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134(4): 960-74.
99. Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007; 5(10): 1214-20.
100. Friedrich-Rust M, S. Z. Reproducibility and limitations of transient elastography. Liver International 2009; 29(5): 619-20.